Last updated on March 2019

Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)


Brief description of study

This is a randomized, open-label, multicenter, phase III study comparing anthracyclines followed by taxane to anthracyclines followed by taxane plus carboplatin as (neo)adjuvant therapy in patients with triple-negative breast cancer.

Patients with stage II/III operable triple-negative breast cancer are eligible. Patients who need adjuvant chemotherapy after breast surgery as well as patients who need neoadjuvant chemotherapy for TNBC are eligible.

Clinical Study Identifier: NCT02441933

Find a site near you

Start Over

Ulsan University Hospital

Ulsan, Korea, Republic of
  Connect »

Chungbuk university hospital

Cheonju, Korea, Republic of
  Connect »

Boramae Medical Center

Seoul, Korea, Republic of
  Connect »

Asan Medical Center

Seoul, Korea, Republic of
  Connect »

National Cancer Center

Goyang, Korea, Republic of
  Connect »

Bundang Cha Hospital

Seongnam, Korea, Republic of
  Connect »

Gangnam Severance hospital

Seoul, Korea, Republic of
  Connect »

Samsung Medical Center

Seoul, Korea, Republic of
  Connect »